Availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen in paraffin blocks (preferred) or at least unstained slides (for detailed tissue requirements at screening)
Patients must have a formalin-fixed, paraffin-embedded (FFPE) tumor block OR representative hematoxylin and eosin (H&E) and unstained sarcoma tissue slides available for submission to central pathology review; this review is mandatory prior to registration to confirm eligibility
A representative formalin-fixed, paraffin-embedded tumor specimen in paraffin blocks, or at least unstained slides with an associated pathology report documenting ER, PR, and HER negativity. Participants with fewer than unstained slides available at baseline, and not fewer than unstained slides will be eligible upon discussion with Medical Monitor
Availability of formalin-fixed paraffin-embedded (FFPE) tumor block (preferred) or at least unstained slides, collected ? months prior to randomization, with an associated pathology report, if available
Have available archival formalin-fixed paraffin-embedded block(s) containing tumor or at least unstained slides containing tumor.
Have available formalin-fixed paraffin embedded (FFPE) tumor tissue sample blocks for submission. If blocks are not available, have unstained slides for submission for central programmed death-ligand (PD-L) testing.
Representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen in paraffin blocks (preferred) or at least unstained slides, with an associated pathology report documenting ER, PgR, and HER negativity
Representative formalin-fixed paraffin-embedded tumor specimens from surgical resection (i.e., radical cystectomy, nephroureterectomy, or lymph node dissection) in paraffin blocks (blocks preferred) or at least unstained slides, with an associated pathology report, for central testing and determined to be evaluable for tumor programmed death-ligand (PD-L) expression prior to study enrollment
Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens (metastatic specimens preferable but if not available primary tumor specimens that are at least muscle-invasive are acceptable) in paraffin blocks (blocks preferred) or at least unstained slides. If archival tissue is not available, subjects may be considered for enrollment on a case by case basis after discussion with the sponsor-investigator
A representative, formalin-fixed, paraffin-embedded (FFPE) tumor specimen in a paraffin block (preferred) or slides containing unstained, freshly cut, serial sections must be submitted along with an associated pathology report prior to study entry. If slides are not available or the tissue block is not of sufficient size, the patient may still be eligible for the study, after discussion with and approval by the Medical Monitor
Availability of a representative formalin-fixed paraffin-embedded (FFPE) tumour block (preferred) or at least unstained slides with an associated pathology report, if available
Availability of a paraffin-embedded or frozen tumor-tissue block with a minimum of cm^ of tumor surface area, or unstained slides from the glioblastoma tissue specimen if a tumor block cannot be submitted
Availability of a paraffin-embedded or frozen tumor-tissue block with a minimum of cm^ of tumor surface area, or unstained slides from the tumor tissue specimen if a tumor block cannot be submitted
Archived or freshly biopsied primary and/or bone metastatic tumor tissue available in paraffin-embedded blocks or slides that is expected to yield slides
Patients must be willing to provide archival tissue from prior biopsy or surgery for prostate cancer, if available\r\n* A formalin-fixed paraffin-embedded (FFPE) tumor specimen in a paraffin block (preferred) or at least slides containing unstained, freshly cut, serial sections must be submitted along with an associated pathology report before study enrollment
A formalin-fixed paraffin embedded tumor block (preferred) or unstained slides must be available from a prior biopsy of the primary tumor or lymph node; a minimum of slides must be available
Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks (preferred) or in freshly cut and unstained slides (exceptional cases) with an associated pathology report for central testing
Representative tumor tissue specimens (paraffin block preferred)
Stratum : Recurrent or refractory primary malignant CNS tumor patients must have adequate pre-trial frozen or formalin-fixed paraffin-embedded (FFPE) tumor material (minimum of unstained slides) available for use in the tumor mutation burden studies
Cohort (MTD) only: patient willing to have paraffin-embedded slides of the primary pancreas tumor or metastatic site, if available, sent to Mayo investigators for this study
Confirmed availability of representative tumor specimens in paraffin blocks/unstained slides
Representative tumor specimens in paraffin blocks (preferred) or at least unstained slides, with an associated pathology report
The subject has available at the site a representative, formalin-fixed, paraffin-embedded, tumor specimen that enabled the definitive diagnosis of breast cancer with adequate viable tumor cells in a tissue block (preferred) or ? ( preferred) freshly cut, unstained, serial slides and the associated pathology report
A formalin-fixed, paraffin-embedded tumor block (or unstained sections [charged, um]) of the biopsy or curettage must be submitted along with the corresponding pathology report; patients without such material, but willing to undergo repeat biopsy or curettage, are eligible; repeat biopsy must occur after consent but prior to randomization
Patients for whom a formalin-fixed, paraffin-embedded tumor block (or unstained sections [charged, um]) of the biopsy or curettage are unavailable and patient is unwilling to undergo repeat biopsy or curettage
Patients must have a formalin-fixed, paraffin-embedded (FFPE) tumor block OR representative hematoxylin and eosin (H&E) and unstained myxoid liposarcoma tissue slides available for submission to central pathology review; this review is mandatory prior to registration to confirm eligibility
Paraffin-embedded tumor block(s) or to unstained slides available for centralized assessment of ER, PR, and HER.
Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks or at least unstained slides, with an associated pathology report, for central testing of tumor PD-L expression.
Pathology: representative urothelial carcinoma FFPE tumor specimens (tumor blocks or unstained slides); patients with < slides may be enrolled after discussion with the principal investigator
Subject has available formalin-fixed, paraffin-embedded tumor specimen with adequate viable tumor cells in a tissue block or unstained serial slides accompanied by an associated pathology report prior to enrollment. Archival or fresh biopsy tissue is required.
Histologically confirmed definitive GBM or gliosarcoma by partial or complete surgical resection (i.e. not by biopsy only) within weeks prior to PLX administration (CD). Tumor must have a supratentorial component. For all patients, availability of a surgical paraffin tumor block sufficient to generate at least unstained slides; or, if a paraffin tumor block is unavailable, at least unstained slides.
The mutational analysis (SNaPSHOT panel) requires a paraffin-embedded block or ten unstained slides from the untreated biopsy specimen obtained at the time of upper endoscopy or initial diagnostic biopsy; patients without sufficient material for SNaPSHOT will NOT be excluded from the study
Paraffin-embedded and/or snap-frozen tumor tissue samples (from primary tumor or metastasis) taken as part of routine clinical care must be available for study related correlative studies; if paraffin-embedded and/or snap-frozen tumor tissue samples are not available, at least unstained tumor slides will be requested
Availability of unstained slides or paraffin-embedded tissue block from archived tumor specimen
Availability of a formalin-fixed paraffin-embedded block containing tumor tissue or unstained tumor slides suitable for PD-L expression assessment.
Availability of a pretreatment tumor biopsy (excluding fine needle aspiration and cytology samples) taken after the subject has discontinued sorafenib and within days before the day of first dosing with MSCJ. From the pretreatment biopsy either a formalin-fixed (formalin fixation is mandatory) paraffin-embedded block with tumor tissue (preferred) or at least unstained slides must be sent to the central laboratory prior to enrollment. An associated pathology report must also be sent with the sample
Availability at the site of tumor specimens in paraffin blocks (preferred) or unstained slides, with an associated pathology report, prior to study entry
Confirmation of availability of sufficient tissue from a prior surgery for correlative studies is required prior to enrollment; patients must have representative non-transitional cell carcinoma (non-TCC) or the urothelial tract formalin-fixed paraffin-embedded (FFPE) archival tumor specimens (tumor blocks or unstained slides; preference for tumor blocks); these samples may be submitted between the time of consent and the start of treatment; patients with < slides may be enrolled after discussion with the principal or co-principal investigators
Availability of a paraffin-embedded or frozen tumor-tissue block with a minimum of cm^ of tumor surface area from a tissue specimen that demonstrates pathological transformation to glioblastoma (WHO grade IV) or a progressive specimen that harbors one of the genetic alterations\r\n* If a tumor block cannot be submitted, then unstained slides (preferably slides from two different tumor blocks from the same surgery) from the tumor specimen must be submitted
Paraffin-embedded and/or snap-frozen tumor tissue samples from the diagnostic procedure must be available for study-related correlative studies; if paraffin-embedded and/or snap-frozen tumor tissue samples are not available, at least unstained tumor slides will be requested
Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks (blocks preferred) or at least unstained slides, with an associated pathology report, for central testing and determined to be evaluable for tumor PD-L expression prior to study enrollment; participants who have fewer than unstained slides available at baseline (but no less than [<] ) may be eligible following discussion with the Medical Monitor